Get the Stockscreener App
13.08
0.31%
0.04
After Hours:
13.08
Zymeworks Inc. stock is traded at $13.08, with a volume of 374.16K.
It is up +0.31% in the last 24 hours and up +3.81% over the past month.
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidate is ZW25, a novel bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer. It is also developing ZW49, a bispecific antibody-drug conjugate that is in IND application stage. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with Celgene Corporation. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
See More
Previous Close:
$13.04
Open:
$12.88
24h Volume:
374.16K
Relative Volume:
0.66
Market Cap:
$910.76M
Revenue:
$62.71M
Net Income/Loss:
$-112.51M
P/E Ratio:
-8.6623
EPS:
-1.51
Net Cash Flow:
$-96.01M
1W Performance:
+4.22%
1M Performance:
+3.81%
6M Performance:
-8.60%
1Y Performance:
+47.30%
1-Day Range:
$12.75
$13.11
1-Week Range:
$12.16
$13.14
52-Week Range:
$8.83
$17.70
Zymeworks Inc. Stock (ZYME) Company Profile
Name
Zymeworks Inc.
Sector
Industry
Phone
604-678-1388
Address
1385 West 8th Avenue, Suite 540, Vancouver, BC
Compare ZYME with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
13.08 | 910.76M | 62.71M | -112.51M | -96.01M | -1.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.41 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
538.11 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.13 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
546.04 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
240.99 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Initiated | TD Cowen | Buy |
| Dec-16-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-07-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-01-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-21-23 | Resumed | Wells Fargo | Overweight |
| Jan-04-23 | Reiterated | H.C. Wainwright | Neutral |
| Dec-20-22 | Upgrade | Jefferies | Hold → Buy |
| Nov-01-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-21-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-04-22 | Resumed | Wells Fargo | Overweight |
| May-05-22 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-15-22 | Initiated | Evercore ISI | Outperform |
| Dec-10-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-17-21 | Resumed | Guggenheim | Neutral |
| Oct-07-21 | Initiated | Jefferies | Hold |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Feb-25-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-08-21 | Resumed | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | Citigroup | Buy → Neutral |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Aug-06-20 | Initiated | SVB Leerink | Outperform |
| Jan-10-20 | Initiated | Wolfe Research | Outperform |
| Dec-09-19 | Initiated | JP Morgan | Neutral |
| Nov-25-19 | Initiated | H.C. Wainwright | Buy |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Sep-30-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-30-19 | Initiated | Stifel | Buy |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| May-11-18 | Upgrade | Barclays | Underweight → Equal Weight |
| Mar-19-18 | Initiated | Raymond James | Outperform |
View All
Zymeworks Inc. Stock (ZYME) Latest News
Wall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High? - MSN
Zymeworks Inc (NASDAQ:ZYME) Valuation Biotech Sector Trends S&P 500 - Kalkine Media
There's Reason For Concern Over Zymeworks Inc.'s (NASDAQ:ZYME) Price - simplywall.st
SG Americas Securities LLC Raises Position in Zymeworks Inc. (NYSE:ZYME) - Defense World
Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade) (ZYME) - Seeking Alpha
Bank of America Corp DE Sells 38,030 Shares of Zymeworks Inc. (NYSE:ZYME) - Defense World
Transcript : Zymeworks Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 02 - MarketScreener
Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge - MSN
ZYMEZymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results - Revista ADVFN
Zymeworks Inc. (NYSE:ZYME) Shares Acquired by Nuveen Asset Management LLC - Defense World
Zymeworks Inc. (NYSE:ZYME) Shares Sold by Jane Street Group LLC - Defense World
BNP Paribas Financial Markets Takes $108,000 Position in Zymeworks Inc. (NYSE:ZYME) - Defense World
Zymeworks gets China's conditional approval for biliary tract cancer treatment - MSN
Ameriprise Financial Inc. Sells 15,800 Shares of Zymeworks Inc. (NYSE:ZYME) - Defense World
Zymeworks Announces NMPA Approval of Zanidatamab in China - GlobeNewswire
Zymeworks gets China's conditional nod for BeOne-partnered cancer treatment - Seeking Alpha
Zymeworks Inc. Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-High expression (IHC3+ Biliary Tract Cancer - marketscreener.com
Zymeworks’ Zanidatamab Receives NMPA Approval in China for HER2+ Biliary Tract Cancer - TipRanks
Zymeworks (ZYME) Receives China's Approval for Zanidatamab in Cancer Treatment | ZYME Stock News - GuruFocus
Zymeworks' Zanidatamab Approved in China for HER2-High Expression Biliary Tract Cancer - marketscreener.com
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer - GlobeNewswire
Zymeworks Inc. announces the closing of its previously announced underwritten public offering - McCarthy Tétrault
Zymeworks Inc. (NYSE:ZYME) Shares Sold by D. E. Shaw & Co. Inc. - Defense World
What is HC Wainwright’s Forecast for Zymeworks Q2 Earnings? - Defense World
Zymeworks Showcases Oncology Advances at Major Conferences - TipRanks
Zymeworks Inc. Showcases Azymetric™ Platform and Clinical Progress of Ziihera® at ASCO and ESMO Conferences - Nasdaq
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences - GlobeNewswire
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences - GlobeNewswire Inc.
TD Cowen Initiates Coverage on Zymeworks (NYSE:ZYME) - Defense World
TD Securities Initiates Coverage on Zymeworks (NYSE:ZYME) - Defense World
Zymeworks Announces Participation in Upcoming Investor Conferenc - GuruFocus
Zymeworks to Engage Investors at Upcoming Conferences - TipRanks
Zymeworks Announces Participation in Upcoming Investor Conferences - The Manila Times
Zymeworks Inc. Announces Upcoming Participation in Key Investor Conferences in June 2025 - Nasdaq
Zymeworks Lines Up Triple Conference Presence: Jefferies, Goldman Sachs, and Citi Healthcare Events - Stock Titan
Zymeworks Inc. (NYSE:ZYME) Shares Acquired by Northern Trust Corp - Defense World
TD Securities Initiates Coverage of Zymeworks (ZYME) with Buy Recommendation - Nasdaq
Zymeworks (ZYME) Initiated as a Buy by TD Cowen Due to Strong Pi - GuruFocus
Zymeworks initiated with a Buy at TD Cowen on Ziihera's opportunities - Seeking Alpha
Zymeworks (ZYME) Receives New Buy Rating from TD Securities | ZYME Stock News - GuruFocus
TD Cowen Initiates Coverage on Zymeworks With Buy Rating - marketscreener.com
Zymeworks (ZYME) Gains Favor with Buy Rating from TD Cowen | ZYM - GuruFocus
Zymeworks Presents Preclinical Data on ZW1528 at the American Th - GuruFocus
Zymeworks (ZYME) Reveals Promising Preclinical Results for ZW152 - GuruFocus
Zymeworks Shows Positive Preclinical Data for Experimental Respiratory Imflammation Treatment - marketscreener.com
Zymeworks Unveils Promising Preclinical Data for Novel Respiratory Treatment - TipRanks
Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference - The Manila Times
Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference | ZYME Stock News - GuruFocus
The Manufacturers Life Insurance Company Sells 1,089 Shares of Zymeworks Inc. (NYSE:ZYME) - Defense World
Price T Rowe Associates Inc. MD Raises Stock Position in Zymeworks Inc. (NYSE:ZYME) - Defense World
Wall Street Analysts Think Zymeworks (ZYME) Could Surge 83.89%: Read This Before Placing a Bet - NewsBreak: Local News & Alerts
Zymeworks Inc. Stock (ZYME) Financials Data
Revenue
Net Income
Cash Flow
EPS
Zymeworks Inc. Stock (ZYME) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| EcoR1 Capital, LLC | Director |
May 19 '25 |
Buy |
11.78 |
5,919 |
69,738 |
17,883,908 |
| EcoR1 Capital, LLC | Director |
Apr 16 '25 |
Buy |
11.16 |
73,953 |
825,589 |
17,773,727 |
| EcoR1 Capital, LLC | Director |
Apr 17 '25 |
Buy |
11.52 |
54,760 |
630,819 |
17,828,487 |
| EcoR1 Capital, LLC | Director |
Apr 04 '25 |
Buy |
11.17 |
196,438 |
2,193,800 |
17,699,774 |
| EcoR1 Capital, LLC | Director |
Apr 03 '25 |
Buy |
11.84 |
120,770 |
1,430,170 |
17,503,336 |
| EcoR1 Capital, LLC | Director |
Apr 02 '25 |
Buy |
11.85 |
74,360 |
881,017 |
17,382,566 |
| EcoR1 Capital, LLC | Director |
Apr 01 '25 |
Buy |
11.60 |
48,658 |
564,647 |
17,308,206 |
| EcoR1 Capital, LLC | Director |
Mar 31 '25 |
Buy |
11.75 |
4,397 |
51,658 |
17,259,548 |
| EcoR1 Capital, LLC | Director |
Mar 25 '25 |
Buy |
12.91 |
53,501 |
690,452 |
17,211,303 |
| EcoR1 Capital, LLC | Director |
Mar 26 '25 |
Buy |
12.24 |
43,848 |
536,857 |
17,255,151 |
1.08%
2.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):